Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25640010 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL7263734 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL26032485 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL12238318 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL13699509 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL25257785 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL14671684 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL12092148 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL22939187 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL25639770 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 338 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4227300-B1 | TRUNCATED EVANS BLUE MODIFIED FIBROBLAST ACTIVATION PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | YANTAI LANNACHENG BIOTECHNOLOGY CO LTD (CN) | 2026-01-28 | — | — | EP | claimed |
| CN-118206611-A | Cell surface protein targeting compound and cell surface protein enrichment method | 中国科学院大连化学物理研究所 | 2024-06-18 | — | — | CN | claimed |
| US-11975079-B2 | Truncated Evans Blue modified fibroblast activation protein inhibitor, preparation method and application thereof | YANTAI LANNACHENG BIOTECHNOLOGY CO., LTD. (CN) | 2024-05-07 | — | — | US | claimed |
| US-20230390421-A1 | TRUNCATED EVANS BLUE MODIFIED FIBROBLAST ACTIVATION PROTEIN INHIBITOR, PREPARATION METHOD AND APPLICATION THEREOF | YANTAI LANNACHENG BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-07 | — | — | US | claimed |
| EP-4227300-A1 | TRUNCATED EVANS BLUE MODIFIED FIBROBLAST ACTIVATION PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Yantai Lannacheng Biotechnology Co., Ltd. (CN) | 2023-08-16 | — | — | EP | claimed |
| US-20190352625-A1 | MUTANTS OF COCAINE ESTERASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2019-11-21 | — | — | US | claimed |
| US-10160960-B2 | Mutants of cocaine esterase | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-12-25 | — | — | US | claimed |
| US-20160177277-A1 | MUTANTS OF COCAINE ESTERASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-06-23 | — | — | US | claimed |
| WO-2015021187-A1 | MUTANTS OF COCAINE ESTERASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-02-12 | — | — | WO | claimed |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-05-21 | — | — | US | disclosed |
| CN-120590466-B | Compound of targeted fibroblast activation protein and application thereof | 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) | 2026-05-12 | — | — | CN | disclosed |
| US-20260118357-A1 | TETRA-FUNCTIONAL CHEMICAL PROBE AND METHOD FOR IDENTIFYING TARGET MEMBRANE PROTEIN FROM LIVING CELL OR LIVING TISSUE BY USING SAID PROBE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2026-04-30 | — | — | US | disclosed |
| EP-4073062-B1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2026-04-29 | — | — | EP | disclosed |
| EP-4733308-A1 | FAP-TARGETING COMPOUND, AND RADIONUCLIDE-LABELED COMPLEX BASED THEREON, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2026-04-29 | — | — | EP | disclosed |
| US-20080213175-A1 | Click chemistry-derived cyclic peptidomimetics as integrin markers | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2008-09-04 | — | — | US | disclosed |
| US-7371585-B2 | Membranes incorporating recognition moieties | GENENCOR INTERNATIONAL, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371585-B2 | Membranes incorporating recognition moieties | GENENCOR INTERNATIONAL, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| WO-2008033557-A2 | CLICK CHEMISTRY-DERIVED CYCLIC PEPTIDOMIMETICS AS INTEGRIN MARKERS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1887359-A1 | Methods for the identification of PI3K interacting molecules and for the purification of PI3K | CELLZOME AG (DE) | 2008-02-13 | — | — | EP | disclosed |
| WO-2008015013-A1 | METHODS FOR THE IDENTIFICATION OF PI3K INTERACTING MOLECULES AND FOR THE PURIFICATION OF PI3K | CELLZOME AG (DE) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080213175-A1 | Click chemistry-derived cyclic peptidomimetics as integrin markers | ITGB1, ITGAM, ITGB3 | MEN1 787/4885KMT2A 4133/4885GAA 2452/4885 |
| US-20230390421-A1 | TRUNCATED EVANS BLUE MODIFIED FIBROBLAST ACTIVATION PROTEIN INHIBITOR, PREPARATION METHOD AND APPLICATION THEREOF | FIBP, FAP, ANPEP | MEN1 808/4885KMT2A 3250/4885GAA 178/4885 |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | FSHR, GNRHR, LHCGR | MEN1 688/4885KMT2A 1938/4885GAA 4537/4885 |
| US-11975079-B2 | Truncated Evans Blue modified fibroblast activation protein inhibitor, preparation method and application thereof | FIBP, FAP, ANPEP | MEN1 808/4885KMT2A 3250/4885GAA 178/4885 |
| US-20260118357-A1 | TETRA-FUNCTIONAL CHEMICAL PROBE AND METHOD FOR IDENTIFYING TARGET MEMBRANE PROTEIN FROM LIVING CELL OR LIVING TISSUE BY USING SAID PROBE | BTD, FABP2, FABP3 | MEN1 4433/4885KMT2A 3600/4885GAA 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.